Sprimeo

RSS

Withdrawn

This medicine's authorisation has been withdrawn

aliskiren
MedicineHumanWithdrawn

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 22 August 2007 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Sprimeo (aliskiren). Sprimeo was approved for the treatment of essential hypertension. The marketing authorisation holder (MAH) responsible for Sprimeo was Novartis Europharm Ltd. 

The European Commission was notified by letter dated 10 June 2012 of the MAH’s decision to voluntarily withdraw the marketing authorisation for Sprimeo for commercial reasons. On 4 July 2012 the European Commission issued a decision to withdraw the marketing authorisation for Sprimeo. 

Pursuant to this decision the European Public Assessment Report for Sprimeo is updated to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (342.15 kB - PDF)

Bekijk

español (ES) (259.26 kB - PDF)

Bekijk

čeština (CS) (311.96 kB - PDF)

Bekijk

dansk (DA) (258.54 kB - PDF)

Bekijk

Deutsch (DE) (260.03 kB - PDF)

Bekijk

eesti (ET) (258.16 kB - PDF)

Bekijk

ελληνικά (EL) (347.65 kB - PDF)

Bekijk

français (FR) (319.2 kB - PDF)

Bekijk

italiano (IT) (259.5 kB - PDF)

Bekijk

latviešu (LV) (316.27 kB - PDF)

Bekijk

lietuvių (LT) (282.88 kB - PDF)

Bekijk

magyar (HU) (307.75 kB - PDF)

Bekijk

Malti (MT) (311.55 kB - PDF)

Bekijk

Nederlands (NL) (259.07 kB - PDF)

Bekijk

polski (PL) (372.79 kB - PDF)

Bekijk

português (PT) (335.06 kB - PDF)

Bekijk

română (RO) (282.51 kB - PDF)

Bekijk

slovenčina (SK) (310.95 kB - PDF)

Bekijk

slovenščina (SL) (308.01 kB - PDF)

Bekijk

suomi (FI) (318.25 kB - PDF)

Bekijk

svenska (SV) (319.06 kB - PDF)

Bekijk

Product information

български (BG) (2.32 MB - PDF)

Bekijk

español (ES) (1.03 MB - PDF)

Bekijk

čeština (CS) (1.65 MB - PDF)

Bekijk

dansk (DA) (1.09 MB - PDF)

Bekijk

Deutsch (DE) (1.14 MB - PDF)

Bekijk

eesti (ET) (1.09 MB - PDF)

Bekijk

ελληνικά (EL) (2.29 MB - PDF)

Bekijk

français (FR) (1.15 MB - PDF)

Bekijk

italiano (IT) (1.14 MB - PDF)

Bekijk

latviešu (LV) (1.74 MB - PDF)

Bekijk

lietuvių (LT) (1.06 MB - PDF)

Bekijk

magyar (HU) (1.7 MB - PDF)

Bekijk

Malti (MT) (1.81 MB - PDF)

Bekijk

Nederlands (NL) (1.08 MB - PDF)

Bekijk

polski (PL) (1.73 MB - PDF)

Bekijk

português (PT) (1.02 MB - PDF)

Bekijk

română (RO) (1.07 MB - PDF)

Bekijk

slovenčina (SK) (1.79 MB - PDF)

Bekijk

slovenščina (SL) (1.68 MB - PDF)

Bekijk

suomi (FI) (1.03 MB - PDF)

Bekijk

svenska (SV) (1019.89 kB - PDF)

Bekijk

Íslenska (IS) (1.1 MB - PDF)

Bekijk

norsk (NO) (1.11 MB - PDF)

Bekijk
Latest procedure affecting product information:II/0039
04/07/2012
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (427.3 kB - PDF)

Bekijk

español (ES) (369.76 kB - PDF)

Bekijk

čeština (CS) (387.75 kB - PDF)

Bekijk

dansk (DA) (344.96 kB - PDF)

Bekijk

Deutsch (DE) (351.03 kB - PDF)

Bekijk

eesti (ET) (348.09 kB - PDF)

Bekijk

ελληνικά (EL) (430.1 kB - PDF)

Bekijk

français (FR) (373.1 kB - PDF)

Bekijk

italiano (IT) (367.54 kB - PDF)

Bekijk

latviešu (LV) (369.95 kB - PDF)

Bekijk

lietuvių (LT) (374.13 kB - PDF)

Bekijk

magyar (HU) (385.82 kB - PDF)

Bekijk

Malti (MT) (389.44 kB - PDF)

Bekijk

Nederlands (NL) (365.63 kB - PDF)

Bekijk

polski (PL) (399.45 kB - PDF)

Bekijk

português (PT) (369.22 kB - PDF)

Bekijk

română (RO) (369.48 kB - PDF)

Bekijk

slovenčina (SK) (390.13 kB - PDF)

Bekijk

slovenščina (SL) (399.01 kB - PDF)

Bekijk

suomi (FI) (344.56 kB - PDF)

Bekijk

svenska (SV) (370.53 kB - PDF)

Bekijk

Íslenska (IS) (367.27 kB - PDF)

Bekijk

norsk (NO) (369.99 kB - PDF)

Bekijk

Product details

Name of medicine
Sprimeo
Active substance
aliskiren
International non-proprietary name (INN) or common name
aliskiren
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09XA02

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Treatment of essential hypertension.

Authorisation details

EMA product number
EMEA/H/C/000851
Marketing authorisation holder
Novartis Europharm Ltd.

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

Marketing authorisation issued
22/08/2007
Withdrawal of marketing authorisation
04/07/2012
Revision
5

Assessment history

This page was last updated on

Share this page